読み込み中
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
前日終値
$8.83
−$0.32 · -3.50%
日中の時刻はETです。市場データは遅延する場合があります。
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
日中レンジ
現在 $8.83
52週レンジ
現在 $8.83
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
32
割高
センチメント
55
まちまち
リスク
51
やや高いリスク
モメンタム
92
強い上昇
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
日中レンジ
現在 $8.83
52週レンジ
現在 $8.83
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|
| 売上原価 | 57.8万 USD | 70.1万 USD | 55.6万 USD | 57.4万 USD |
| 粗利益 | −57.8万 USD | −70.1万 USD | −55.6万 USD | −57.4万 USD |
| 研究開発 | 1.38億 USD | 6782.2万 USD | 4911.9万 USD | 2657万 USD |
| 販売・一般管理 | 3073.4万 USD | 1442.3万 USD | 760.7万 USD | 410.1万 USD |
| 営業費用 | 1.69億 USD | 8224.5万 USD | 5672.6万 USD | 3067.1万 USD |
| 受取利息 | 551.8万 USD | 450.4万 USD | 109.9万 USD | 42.9万 USD |
| 減価償却費と償却費 | 57.8万 USD | 70.1万 USD | 55.6万 USD | 57.4万 USD |
| 営業利益 | −1.69億 USD | −8294.6万 USD | −5728.2万 USD | −3124.5万 USD |
| 純利益 | −1.61億 USD | −7758万 USD | −5570.9万 USD | −3001.6万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$29.20
上昇余地（230.69%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI716.31万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM300.42万0.00%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF282.31万0.00%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO95.79万0.01%139.17億 USD0.24%$356.78+0.94%
Schwab U.S. Small-Cap ETFSCHA83.72万0.00%218.24億 USD0.03%$32.79+0.40%
Vanguard Russell 2000 ETFVTWO77.46万0.00%180億 USD0.06%$112.66+0.50%
Fidelity Enhanced Small Cap ETFFESM56.35万0.01%64.1億 USD0.28%$45.46+0.46%
Vanguard Health Care ETFVHT40.79万0.00%220億 USD0.09%$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMVanguard Health Care ETFVHTAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
